Palonosetron, Netupitant

5 trials 2 recruiting AGastroenterology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

4 Sponsors

13 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 1

Oversight events:

3 temporary halts 6 urgent safety measures across 2 trials

View oversight register →

Indications tested

Myelofibrosis 1 Papillary serous endometrial carcinoma 1

Sponsors using this IMP

K-Group Beta Inc. 2 Eli Lilly & Co. 1 Fondazione IRCCS Istituto Nazionale Dei Tumori 1 Karyopharm Therapeutics Inc. 1

All trials

5 total

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending

2025-522204-24-00 Phase II 4 countries Eli Lilly & Co.
Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting

2022-502983-19-00 Phase II 5 countries K-Group Beta Inc.
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting

2023-504150-35-00 Phase IV 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 Phase II 3 countries K-Group Beta Inc.

Showing 1–5 of 5 trials

← All drugs A–Z